Place of captopril in the therapy of uncompli hypertensive crisis
- Authors: Taratukhin Y.O.1, Luchinkina Y.Y.1
-
Affiliations:
- N.I. Pirogov Russian National Research Medical University
- Issue: No 1 (2017)
- Pages: 129-134
- Section: Articles
- URL: https://journals.eco-vector.com/2412-4036/article/view/277680
- ID: 277680
Cite item
Open Access
Access granted
Abstract
The article is devoted to new information about captopril (Capoten) - a quick-relief drug for the treatment of uncomplicated hypertensive crisis. The epidemiological data on the issue are presented; modern literature on studies of this drug is considered. Pleiotropic effects of captopril and its potential use outside the hypertension are discussed.
Full Text
About the authors
Yeugeniy O. Taratukhin
N.I. Pirogov Russian National Research Medical University
Email: cardio03@list.ru
PhD, Associate Professor, Department of Hospital Therapy №1, Medical Faculty
Yelena Ye. Luchinkina
N.I. Pirogov Russian National Research Medical UniversityPhD, Associate Professor, Department of Hospital Therapy №1, Medical Faculty
References
- Здравоохранение в России 2015. Москва: Росстат 2015. 174 с. [Health care in Russia 2015. Moscow: Rosstat 2015. 174 p. (in Russ.)]
- Global status report on non-communicable diseases. Switzerland: WHO, 2015. 302 p.
- Mancia G., Fagard R., Narkiewicz K., et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2013;34(28):2159-219.
- Крюков Е.В., Потехин Н.П., Фурсов А.Н., Чернецов В.А., Чернов С.А., Захарова Е.Г. Гипертонический криз: современный взгляд на проблему и оптимизация лечебно-диагностических подходов. Клиническая медицина. 2016;94(1 ):52-6. [Kryukov Ye.V., Potekhin N.P., Fursov A.N., Chernetsov V.A., Chernov S.A., Zakharova Ye.G. Hypertensive crisis: modern view of the problem and optimization of diagnostic and therapeutic modalities. Klinicheskaia meditsina. 2016;94(1):52-6 (in Russ.)]
- Antunes A. M., Guerrante R. D., Avila J. P., Lins Mendes F.M., Fierro I.M. Case study of patents related to captopril, Squibb's first blockbuster. Expert Opin. Ther. Pat. 2016;26(12):1449-57.
- Kaya A., Tatlisu M. A., Kaplan Kaya T., Yildirimturk O., Gungor B., Karatas B., Yazici S., Keskin M., Avsar S., Murat A. Sublingual vs. oral captopril in hypertensive crisis. J. Emerg. Med. 2016;50(1):108-15.
- Torika N., Asraf K., Roasso E., Danon A., Fleisher-Berkovich S. Angiotensin converting enzyme inhibitors ameliorate brain inflammation associated with microglial activation: possible implications for alzheimer's disease. J. Neuroim. Pharmacol. 2016;11(4):774-85.
- Abbasi S., Yousefi G., Ansari A. A., Mohammadi-Samani S. Formulation and in vitro evaluation of a fast-disintegrating/ sustained dual release bucoadhesive bilayer tablet of captopril for treatment of hypertension crises. Research in pharmaceutical sciences. 2016;1 1(4):274-83.
- Nair R.S., Nair S. Permeation studies of captopril transdermal films through human cadaver skin. Current drug delivery. 2015;12(5):517-23.
- Khaled S.A., Burley J.C., Alexander M.R., Yang J., Roberts C.J. 3D printing of tablets containing multiple drugs with defined release profiles. Int. J. Pharm. 2015;494(2):643-50.
- Sirisha P.L., Babu G.K., Babu P.S. Conceptuation, formulation and evaluation of sustained release floating tablets of captopril compression coated with gastric dispersible hydrochlorothiazide using 2(3) factorial design. Int. J. Pharm Invest. 2014;4(2):77-87.
- Popa C.D., van Riel P.L. The use of captopril in rheumatoid arthritis: combining treatment targets! Can. J. Cardiol. 2013;29(5):639.e13.
- Repova-Bednarova K., Aziriova S., Hrenak J., Krajcirovicova K., Adamcova M., Paulis L., Simko F. Effect of captopril and melatonin on fibrotic rebuilding of the aorta in 24 hour light-induced hypertension. Physiol. Res. 2013;62 (Suppl. 1):S 135-41.
- Kim J. H., Park K. S., Hong A. R., Shin C.S., Kim S.Y., Kim S.W. Diagnostic role of captopril challenge test in korean subjects with high aldosterone-to-renin ratios. Endocrinol. Metab. (Seoul). 2016;31(2):277-83.
- Kast R.E., Halatsch M.E. Matrix metalloproteinase-2 and -9 in glioblastoma: a trio of old drugs-captopril, disulfiram and nelfinavir-are inhibitors with potential as adjunctive treatments in glioblastoma. Arch. Med. Res. 2012;43(3):243-7.
- Kochi T., Shimizu M., Ohno T., Baba A., Sumi T., Kubota M., Shirakami Y., Tsurumi H., Tanaka T., Moriwaki H. Preventive effects of the angiotensin-converting enzyme inhibitor, captopril, on the development of azoxymethane-induced colonic preneoplastic lesions in diabetic and hypertensive rats. Oncol. Lett. 2014;8(1):223-9.
- Brem J., van Berkel S. S., Zollman D., Lee S.Y., Gileadi O., McHugh P.J., Walsh T.R., McDonough M.A., Schofield C.J. Structural Basis of metallo-beta-lactamase inhibition by captopril stereoisomers. Antimicrob. Agents Chemother. 2015;60(1):142-50.
- Wani-Parekh P., Garcia-Blanco C., Mendez M., Mukherjee D. Hypertensive Crisis: pharmacotherapy and complications. Cardiovasc Hematol Disord Drug Targets. 2016. [Epub ahead of print]
- Muiesan M.L., Salvetti M., Amadoro V., di Somma S., Perlini S., Semplicini A., Borghi C., Volpe M., Saba P.S., Cameli M., Ciccone M.M., Maiello M., Modesti P.A., Novo S., Palmiero P., Scicchitano P., Rosei E.A., Pedrinelli R. An update on hypertensive emergencies and urgencies. J. Cardiovasc. Med. 2015;16(5):372-82.
Supplementary files
